Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
Dario (NASDAQ: DRIO) announced a Collaborative Services Agreement with Beluga Health to deliver provider-backed, digitally enabled chronic care across all 50 states.
The integrated platform combines coaching, AI triage and Beluga’s physician network to monitor, detect and treat conditions including diabetes, hypertension, obesity, behavioral health and musculoskeletal issues, using one vendor relationship.
The partnership targets health plans, health systems, employers and public programs, with evidence from a JMIR study showing Dario users had 23% lower hospitalization rates and 26% lower total charges than matched usual-care patients.
DarioHealth (NASDAQ: DRIO) reported four new studies at the American Diabetes Association Scientific Sessions showing clinical and economic signals from its digital cardiometabolic platform.
Results included 0.23 fewer hospitalizations PPPY, 6.4%–14.3% 12‑month weight loss, and 44.8% of high‑risk diabetes users achieving ≥1% eA1c reduction.
DarioHealth (NASDAQ: DRIO) announced that Solera Health has expanded Dario's digital offerings to include a broader hypertension program, now covering pre-hypertensive members through Stage 2 hypertension.
This more than doubles Dario's addressable market within Solera's network, tying revenue to engagement, longitudinal outcomes and recurring, year-long member experiences.
DarioHealth (NASDAQ: DRIO) reported first quarter 2026 revenue of $5.6 million, up 6.7% sequentially but below $6.8 million a year earlier, mainly due to non-recurring prior pharma revenue. GAAP gross margin was 57%; operating expenses fell to $10.5 million (down 21% YoY), cutting operating loss to $7.3 million. Net loss was $8.2 million. Cash and short-term deposits totaled $20 million, with $6 million net cash used in operations. Channel partnerships provide access to over 116 million covered lives, with a new contract in progress that could raise reach above 175 million. DarioHealth added 10 new accounts and reported a $127 million pipeline across 241 active opportunities.
DarioHealth (Nasdaq: DRIO) will report first quarter 2026 financial results for the period ended March 31, 2026 and will host a live conference call and webcast on Wednesday, May 13, 2026 at 8:30 a.m. ET, before the market opens.
Executives Erez Raphael, Steven Nelson, and Chen Franco-Yehuda will host. A replay will be available through Wednesday, May 27, 2026.
DarioHealth (NASDAQ: DRIO) announced a peer‑reviewed JMIR Formative Research publication (April 20, 2026) reporting statistically significant improvements in workplace functioning from its digital behavioral health program.
Among users, focus and task completion improved within six weeks (n=1,254 for concentration), with larger gains by weeks 6–10; comparable gains seen for procrastination (n=1,004) and mistakes at work (n=167).
DarioHealth (NASDAQ: DRIO) appointed veteran healthcare executive John R. Palumbo to its Board of Directors effective April 13, 2026. Palumbo brings more than 40 years of healthcare operating experience, board service, and relationships across payers, health systems and provider services to support accelerated commercial scaling.
The appointment aligns board composition with a partner-led, capital-efficient go-to-market strategy and aims to expand channel partnerships and commercial momentum.
DarioHealth (NASDAQ: DRIO) reported Q4 2025 revenue of $5.2M and full-year 2025 revenue of $22.4M versus $27.0M in 2024, driven by a legacy client nonrenewal after the Twill acquisition.
Key metrics: GAAP gross margin 57%, pipeline $122M, contracted/late-stage ARR $12.9M, cash $26M, and full-year operating expenses down 31% to $49.3M.
DarioHealth (Nasdaq: DRIO) will report fourth quarter and full year 2025 results before the market opens on Thursday, March 19, 2026.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda. A replay will be available through Thursday, April 2, 2026.
DarioHealth (NASDAQ: DRIO) published a peer-reviewed ML study in Frontiers in Digital Health on March 10, 2026, analyzing real-world data from 22,414 adults with type 2 diabetes.
Researchers used generalized linear mixed-effects tree models and found sustained blood glucose improvements linked to higher digital engagement; 12 measurements per month emerged as an actionable threshold for glycemic improvement.